Chimera in the ancient Greek mythology was a fire-breathing monster that had the head of a lion, the body of a she-goat, and the tail of a dragon. In modern allogeneic stem cell transplantation chimerism describes the presence of donor hematopoietic and lymphoid cells in a transplant recipient. Full donor or complete chimerism (CC) is defined when all hematopoietic and lymphoid cells in the transplant recipient derive from the donor. Mixed chimerism (MC) describes the persistence of host and donor cells together. MC describes a dynamic balance between host and donor hematopoietic cells due to bilateral tolerance. MC may be stable or may be a transient phase following transplantation ultimately leading to CC or to graft rejection. Non-myeloablative stem cell transplantation (NST) represents one of the most significant recent advances in allogeneic transplantation. This approach intends to induce MC as a means to reduce toxicity, and as a platform for allogeneic adoptive cellular immunotherapy.
In this review, we discuss the rationale of the NST approach and the currently investigational NST regimens. We describe how MC affects transplantation outcomes, and how chimerism testing can be used to guide therapeutic interventions following NST.
Rationale for NST
Allogeneic stem cell transplantation is an effective, potentially curative treatment of advanced or high-risk hematologic malignancies, as well as other malignant, and non-malignant disorders.
1,2 Bone marrow transplantation (BMT) was initially developed as a means to deliver high-dose chemotherapy and radiation for elimination of the underlying disorder. Escalation of treatment doses results in better tumor kill but leads to irreversible myelosuppression. BMT was viewed as a supportivecare modality to restore hematopoiesis after treatment. However, it has subsequently become apparent that high-dose chemo-radiotherapy does not eradicate the disease in many patients and that much of the therapeutic benefit of BMT relates to an associated immune-mediated graft-versus-leukemia (GVL) or graft-versus-tumor (GVT) effect. Extensive experimental and clinical data support the presence of a GVL effect. [3] [4] [5] Their thorough discussion is beyond the scope of this review.
High-dose chemo-radiotherapy with allogeneic BMT is associated with significant morbidity and mortality due to the toxicity of the preparative regimen, graft-versus-host disease (GVHD), and the immunodeficient state that accompanies the procedure. The risk of regimen-related toxicity and GVHD increases with advanced age, limiting standard BMT to younger patients who are in good general condition. Extensive research has been directed towards the development of safer and less toxic approaches to allogeneic transplantation. The discovery of the curative potential of the immune-mediated GVL/GVT effect has led to a novel therapeutic approach. Lowdose, relatively non-toxic and tolerable conditioning regimens have been designed, not to eradicate the malignancy, but rather to provide sufficient immunosuppression to achieve engraftment and to allow induction of GVL as the primary treatment. [3] [4] [5] NST does not eliminate all host hematopoiesis and commonly leads to a state of MC. MC describes persistence of donor cells with either benign host hematopoietic cells and/or cells of the underlying malignancy ( Figure 1 ). Stable long-lived MC has been reported in animal models and in patients having NST for non-malignant disorders. However, in patients with malignancies, MC is most often transient and conversion to CC, autologous reconstitution, or relapse occurs either spontaneously or following immune manipulations within the first few months following NST. [5] [6] [7] The initial nonmyeloablative treatment is expected to produce only transient suppression of the underlying malignancy, but it allows time for the immune GVM effect to develop. Patients with benign MC or with detectable residual malignancy post NST may respond to additional immunotherapeutic approaches. Immunosuppressive therapy given post-transplant for prevention of GVHD can also suppress the GVL effect. 8 Early withdrawal of immunosuppressive therapy allows the occurrence of potent graft-versus-hematopoietic tissue effect that can potentially eliminate residual disease and host hematopoiesis NST program: The initial NST regimen induces mixed chimerism with persistence of both donor and recipient hematopoietic cells. The underlying malignancy (m) is suppressed but not completely eliminated. In the second phase, immune-therapeutic interventions, eg withdrawal of immunosuppressive therapy (IST) supplemented if necessary by DLI, induce graft-versus-hematopoietic tissue and graftversus-tumor effects eliminating recipient hematopoiesis and the underlying malignancy and converting to complete chimerism.
Leukemia producing CC (Figure 1) . [9] [10] [11] If this does not occur DLI may harness this effect and switch the balance towards CC. On a few occasions a second non-myeloablative or standard transplant may be required. As reported in animal models, this potent graft-versus-hematopoietic tissue effect can occur in the absence of GVHD. 12 The initial NST and achievement of engraftment thus serve as a platform for additional allogeneic cellular therapy.
NST regimens were originally designed to enable treatment of older patients and patients with comorbidities that preclude standard ablative conditioning. Many hematologic malignancies are more common and have a worse prognosis in the elderly. NST has thus allowed the application of curative therapeutic approach to a much wider patient population. NST regimens are now been explored as ways to reduce toxicity even in younger patients and in patients with benign disorders where high-dose chemo-radiotherapy is obviously unnecessary, and the risks of a standard ablative transplant are unacceptable. Some new exciting indications where NST may be used are induction of transplantation tolerance to solid organs 3, 13, 14 and the treatment of some infectious and autoimmune disorders. 3, 15 NST may have additional advantages. In contrast to standard ablative transplants, following NST autologous reconstitution will generally occur in patients who reject the graft. However, graft failure with no reconstitution has been reported in a minority of patients, usually in the setting of extensive prior therapy and limited stem cell pool, with profoundly active disease, and with stromal defects. 5 GVHD is one of the major causes of post-transplant morbidity and mortality. Animal models have shown that the state of MC allows bilateral transplantation tolerance with graft acceptance and no GVHD. 9, 16, 17 Transplant recipients in these models experience durable engraftment of donor marrow, as well as tolerance of skin or perfused organ allografts from the same donor. The Hadassah group has shown that the balance between host and donor in mixed chimera is mediated by veto effects operative in both directions. 18 Host veto cells, particularly CD8 + cells, surviving the NST regimen, tolerize allogeneic T cells and prevent GVHD. The opposite phenomenon occurs when donor T cells facilitate engraftment. Mega-doses of stem cells may have similar tolerizing effects. 19 Other mechanisms for bilateral tolerance in the NST regimen may occur. Sykes et al 12 used a regimen based on profound T cell depletion of the host and the graft. Newly formed T lymphocytes acquire central tolerance to host and donor antigens present in the thymus. Interestingly, delayed DLI in this model induced complete lympohematopoietic chimerism with no GVHD. Tolerance could also be induced in this model by using costimulation blockade with no need for T cell depletion or any other immunosuppression. 20 Theoretically, this bilateral tolerance may also tolerize against the underlying malignancy and relapse may ultimately occur.
Acute GVHD results at least partially from tissue injury and cytokine release secondary to the toxicity of the preparative regimen, amplified by donor immune cells. Use of less toxic conditioning should theoretically limit tissue injury and cytokine release and reduce the incidence and severity of GVHD. 21, 22 Delayed immune manipulations after tissue injury resolves, as incorporated into NST programs, is less likely to produce severe GVHD. 23, 24 Theoretically, NST may not completely ablate host immunity and allows at least partial protection from certain infections.
NST regimens
Conditioning regimens have been referred to as non-myeloablative if they do not completely eradicate host hematopoiesis and immunity. 4 A few of these regimens have been given with no stem cell support and allow prompt hematological recovery. Autologous reconstitution of hematopoiesis is expected if the allograft is rejected. These non-myeloablative regimens have potent immunosuppressive effects. They are only mildly myelosuppressive and commonly result in induction of MC. More intensive regimens have also been developed. These regimens have been referred to as reduced intensity conditioning regimens. They have not been given without stem cell support and autologous recovery following treatment may be slow. These regimens usually combine immunosuppressive agents with agents with moderate myelosuppressive effects. However dose-intensity is reduced compared to standard ablative regimen allowing reduction of toxicity (Table 1) .
Purine analogues have been the cornerstone of NST regimens. [3] [4] [5] These are well-tolerated agents, with potent immunosuppressive effects, in addition to anti-tumor activity against a range of hematologic malignancies. 25 They have synergistic effects with alkylating agents. Purine analogues inhibit DNA repair systems responsible for repair of cellular damage induced by these agents. The Hadassah group 26 and the MD Anderson group 27 pioneered the use of purine analogues in NST regimens. In Hadassah, Jerusalem, fludarabine has been combined with reduced-dose busulfan and ATG (FB/ATG). This reduced-intensity conditioning regimen was used successfully in more than 150 transplants from related 3, 26 and unrelated donors, 6 for a variety of malignant and nonmalignant disorders. It was well tolerated, even in heavily pretreated patients, such as those failing a prior autologous transplant. 28 The MD Anderson group used a similar reducedintensity conditioning regimen combining fludarabine with melphalan (FM). 7 This regimen was used in elderly patients and patients considered poor candidates for standard transplants, up to the age of 70. Encouraging results have been reported considering the treatment of elderly patients with refractory malignancies.
A variety of non-myeloablative regimens have been developed. The combination of fludarabine and cyclophosphamide (FC) was pioneered at the MD Anderson for the treatment of lymphoid malignancies without stem cell support. It was subsequently used for NST in patients with indolent lymphoid malignancies. 29 The NCI used a similar regimen, with larger doses of cyclophosphamide in a variety of hematologic malignancies and solid tumors. 9 Carella et al 30, 31 used a two-phase approach; high-dose chemotherapy and autologous transplantation for cytoreduction and as an immunosuppressive platform for a subsequent NST with low doses of FC. Similarly, the Flag/Ida regimen was developed initially at MD Anderson for the treatment of AML, and subsequently used as a non-ablative regimen for NST in elderly patients with myeloid malignancies. 5, 27 This regimen was used successfully in patients up to the age of 75. 32 Following the results obtained from their preclinical canine model, 33 the Seattle cooperative group designed a regimen consisting of low-dose TBI (200 cGy) and pre-and post-transplant immunosuppression with cyclosporine and mycophenolate-mofetil to prevent the graft-versus-host and host-versusgraft reactions. This is a very tolerable regimen, allowing ambulatory treatment, and treatment of elderly patients. 34 Sykes et al 12 developed a murine NST model using low- dose TBI or cyclophosphamide combined with thymic radiation, and T cell depletion of the host and allograft. 12 This regimen allowed acceptance of HLA-mismatched grafts with no GVHD. This approach was then explored in men, using a regimen consisting of cyclophosphamide, thymic radiation, and ATG both pre-and post NST.
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Methods for chimerism evaluation
Donor and recipient cells can be distinguished by testing informative genetic markers that are determined prior to the transplant. 37 Table 2 summarizes the currently available methods for detection of chimerism. In sex-mismatched transplant different methods are usually implied to detect the proportion of female and male cells by analysis of sex chromosome markers. In sex-matched transplants informative loci are determined. Within a family up to four alleles may be found in each locus, and informative loci can usually be defined using a panel of genetic markers. The number of alleles at a given locus may be higher in the general population, and easier to identify in transplants from unrelated donors. Chimerism tests need high sensitivity and specificity for detection of small host or donor populations. They need to be reproducible, give Leukemia quantitative assessment, and with a rapid turnover, to allow timely applied clinical interventions The earlier methods of chimerism testing, such as determination of red cell antigens and enzyme polymorphism have largely been replaced by cytogenetics and molecular biology techniques. Standard cytogenetic analysis is informative in sex-mismatched transplants, when the underlying malignancy has a specific cytogenetic marker, and on the rare occasion when the recipient or donor harbor a constitutional cytogenetic abnormality. The sensitivity of chromosomal analysis depends on the number of metaphases examined. Thirty metaphases must be examined to exclude 10% chimerism with 95% confidence. This is an intensive and cumbersome test, with slow turn-over, requires cells in metaphase that are often difficult to obtain, and the results may be biased by an in vitro proliferation advantage of either donor or host cells. It is estimated that the sensitivity of this technique is 1-10%. Regular cytogenetics for chimerism testing has largely been replaced by FISH techniques. FISH is simpler and can be applied to a large number of interphase cells, allowing higher sensitivity. Initial studies analyzed chimeric status following sex-mismatched transplants using Y chromosome-specific probes. The false positive rate of Y-positive cells is 0-2.5%, while the false negative rate is considerably higher, up to 6-13%. 37, 38 The test may be con-Leukemia founded by age or disease-related loss of Y chromosome. The sensitivity and specificity may be markedly improved by simultaneous use of X and Y probes labeled with dual fluorescent colors. 39 Restriction fragment length polymorphism (RFLP) distinguishes donor and host cells by the loss or gain of restriction enzyme cleavage sites, or by insertion or deletion of DNA between restriction sites. The restriction enzyme cleavage pattern can be identified by Southern blot assays. These assays have been largely replaced by PCR because they are complex and cumbersome, their sensitivity is limited (1-10%) and they are not useful for precise quantitation.
Assessment of variable number of tandem repeats (VNTR) or short tandem repeats (STR) polymorphism has become the most valuable method for determination of chimerism in sexmatched transplants. Certain core DNA sequences are tandemly repeated in the genome and the number of tandem repeats varies among different individuals. These repeats differ in base pair length to form microsatellites (2-8 base pairs) or minisatellites (8-50 base pair TG(n) repeats). There are a very large number of loci available for testing, and multiple alleles in each site, allowing identification of informative markers in almost all donor-recipient pairs using a limited panel of loci. VNTR can be identified by Southern blot assays or preferably by DNA amplification of these highly polymorphic sequences. With these PCR tests a minor population of DNA can be detected even when its concentration is as low as 1-5% of the total. 40 More recently, multiplex PCR amplification of STR markers has been applied to chimerism testing. 41 This method uses a commercially available kit originally designed for forensic purposes (genetic fingerprinting) that co-amplifies up to nine STR markers. Whereas the majority of PCR techniques allow only semi-quantitative information, this technique is able to provide reproducible quantitative results.
Assays based on the amplification of a Y chromosome-specific sequence by PCR identify only male cells and are susceptible to false positive and negative results. A second round of nested PCR or many PCR cycles are needed to increase sensitivity and are easy sources of contamination. The gender of human cells can be determined by PCR amplification of the amelogenin (AMG) gene located on chromosome X and its shorter copy located on chromosome Y (AMGY). Pugatsch and the Hadassah research group 42 improved the standard PCR assay, and can now detect both male and female cells simultaneously using DNA from as little as one cell in 10 6 female cells, in a single-step PCR reaction, by the addition of a third primer. AMGY is very similar to AMGX but lacks close to 200 bp: therefore a different junction sequence unique to AMGY is present. A primer spanning this sequence recognizes Y molecules only, and does not compete with the amplification of AMGX. The additional primer amplifies a third product, AMGY2 which is male specific and not detectable in female cells. This method was used successfully by the Hadassah group in sensitive determination of chimerism in sexmismatched transplants.
Chimerism testing detects both benign and malignant cells. More specific tests may detect underlying malignancy when there is a specific tumor marker such as specific cytogenetic abnormality, a specific immunophenotype that can be identified by FACS, specific DNA-RNA sequences that can be amplified by PCR, or a specific growth pattern in clonogenic assays. In the absence of a specific tumor marker for MRD analysis chimerism testing can be used to detect host cells. The sensitivity of the molecular techniques can be increased by applying them to a subset of leukocytes enriched for the minor population. For example, immunophenotyping of an original leukemic clone can be used for FACS sorting. 43 Application of chimerism testing analysis to the sorted population results in two-log increase in the sensitivity of identifying leukemic cells up to 1:10 3 to 1:10 4 . Leukemia cells can also be identified in higher sensitivity within CD34 + selected cells of peripheral blood leukocytes. Chimerism changes in subset population may precede that detected in total leukocytes by weeks to months allowing earlier application of therapeutic interventions.
Subset analysis has an even more important role after NST as MC is common in this setting with both residual malignant and benign hematopoietic cells. Chimerism testing has generally been performed using unseparated bone marrow samples. This mostly detects myeloid chimerism, and may be affected by residual leukemia. Testing of T cell chimerism is, as described below most predictive of allogeneic responses such as GVHD and GVL and is a better factor to follow when applying immune manipulations for conversion from MC to CC and induction of GVL, and when planning the time and intensity of immunosuppressive therapy after NST.
Chimerism testing in clinical decision-making
Conditioning regimens form a continuum from the non-myeloablative regimens, through the reduced intensity regimens, and to the maximally tolerated ablative doses of standard BMT. The role of chimerism testing in the clinical management of BMT recipients differs between these regimens, and also in the different time-points after transplantation. The three phases after BMT, the period from transplantation to hematological engraftment, from engraftment until establishment of CC and the late post-transplant period, have different chimerism kinetics with different therapeutic implications. The optimal timing of chimerism testing and inferable therapy options are under debate, 44, 45 and different approaches have been reported by different groups.
Chimerism testing is used for routine documentation of engraftment in transplant recipients. During the first few weeks after standard myeloablative stem cell transplantation recipient-derived cells can still be found in the blood and marrow of most patients when sensitive tests are used (see below). 38 Most of these cells are host T cells surviving the conditioning regimen. 46 Long-term MC is rare after unmanipulated BMT. It may be more common after T-depleted transplants, but is often stable in this setting and continuous monitoring usually has no clinical implications. Dubovsky et al 40 described the kinetics of engraftment in the early post-transplant period. They monitored pediatric patients during the first days and weeks after standard myeloablative transplantation. Peripheral blood samples were assessed by STR-PCR (see below) at 1-3 day periods. In most patients a pattern of continuous MC was observed within the first 24 h after transplantation and during the following few weeks. Donor cells gradually replace host cells and become dominant by day 14 (median +8, range 2-14) (defined as molecular engraftment) or a median of 7 days (range 1-17) prior to hematologic engraftment. CC was achieved by day +28, most often before hematological engraftment but in 20% of patients simultaneously with engraftment or after hematological engraftment. The early engraftment is apparently produced by committed progenitors and is followed by hematopoiesis derived by pluripotent stem cells. Other patterns have also been observed in which MC became apparent only a few days after transplant or when CC was observed since the first testing. Molecular engraftment occurs most often when the WBC count is less than 100/l but could predict outcome. If molecular engraftment is not achieved by day +14 hematologic engraftment is unlikely to occur. Graft rejection was heralded by reappearance of MC or decreasing donor chimerism. The dynamics of rejection were very rapid sometimes occurring within 48 h of these molecular changes. Intensive chimerism testing as often as a few times weekly during this period may allow early and timely administration of therapeutic intervention such as additional stem cell or lymphocyte infusion and/or a second transplantation in an attempt to save the graft. Less is known about the kinetics of engraftment during this early stage after NST.
A state of MC commonly occurs at the time of hematologic engraftment following non-myeloablative conditioning but unlike standard ablative transplant MC may continue beyond the first few weeks post transplant and immune therapeutic interventions may be required to convert to CC. The balance between donor and recipient cells is determined by the immunosuppressive and myelosuppressive intensity of the conditioning regimen, by the immunocompetence of the recipient as determined by the specific disease and prior therapy and by post-transplant therapy. The genetic disparity between the donor and recipient is another important factor. Table 3 summarizes clinical trials demonstrating these principles. Childs et al 9 described the kinetics of engraftment of different lineages following a non-ablative regimen consisting of FC. T cell engraftment occurred promptly and by day 30, seven of 14 evaluable patients had full donor T cell chimerism. Three additional patients converted to full T cell chimerism following withdrawal of cyclosporine, and three also required DLI. One patient with low-level chimerism rejected the graft. By 6 months all evaluable patients had full T cell chimerism. Myeloid engraftment lagged behind T cell 34 recently reported the Seattle cooperative study with their low-dose TBIbased regimen. Eighty percent of patients had MC early after transplantation. MC was unstable progressing to either CC or graft rejection following cyclosporine withdrawal and/or DLI. DLI was not effective at converting low-level donor chimerism (Ͻ50% donor cells) to CC and most of these patients rejected the graft. Overall, 20% of the patients in this study rejected the graft. These non-ablative regimens result in an initial phase of MC and an inherent need for immune manipulations for conversion to CC in a large proportion of patients. DLI is given as early as 5 weeks post NST and usually within the first 2-3 months. Close monitoring of chimerism, in most studies with weekly testing, allows the clinician to follow these changes from MC to established CC or to autologous reconstitution.
Intensification of the immunosuppressive regimen with agents with additional myelosuppressive effects such as busulfan or melphalan improves engraftment rate and results in rapid achievement of CC (Table 3 ). The kinetics of chimerism following conditioning with these more intensive, reducedintensity regimens, resembles that after ablative conditioning as described above. In the experience of the Hadassah group in Jerusalem with over 150 NST recipients conditioned with fludarabine, busulfan, and ATG, engraftment was prompt, and the median time for conversion to CC was 21 days (range 10-96). DLI for conversion is rarely needed. 47 Similar results have recently been reported by the MD Anderson group with the combination of fludarabine and melphalan. 7 Increasing chimerism may also be achieved by intensification of the immunosuppressive part of the regimen or in patients with reduced immunocompetence due to prior therapy (Table 3) . 22, [48] [49] [50] The Seattle group demonstrated this effect with the addition of fludarabine to their low-dose TBI regimen. 48 The addition of fludarabine to the regimen decreased rejection rates, improved acceptance of unrelated donor grafts, increased the degree of chimerism and reduced the need for DLI. Prior autologous transplant has the same immunosuppressive effect and tends to increase donor chimerism. 50 Carella et al 30, 31 documented this principle using an autologous transplant for cytoreduction and also as a platform for a second allogeneic transplant with minute doses of FC.
More intensive conditioning is required for consistent engraftment of allografts from unrelated donors. Relatively high rates of graft rejection have been reported with non-ablative regimens in the unrelated donor setting. Consistent engraftment has been achieved with the reduced intensity regimens, 6, 7 or when intensifying the non-ablative regimen as described above.
MC at this stage is important in predicting allogeneic responses such as the GVHD and GVT responses. Childs et al 9 have shown that both GVHD and anti-tumor responses occurred only after conversion to complete T cell chimerism. Early achievement of CC resulted in a higher incidence of GVHD. The groups using reduced toxicity regimens noticed the same phenomenon. The Hadassah group reported that with the FB/ATG regimen, conversion to CC occurred promptly but 66% developed acute GVHD, thus only unilateral tolerance was achieved. 47 Other factors such as early discontinuation of immunosuppressive therapy and the use of low-dose cyclosporine alone as GVHD prophylaxis may have contributed to the higher risk of GVHD with this regimen. The MD Anderson group reported similar results with the FM regimen. 7 With the less intensive Flag/Ida regimen this group reported that GVHD rates were lower and only seen in patients at the time of conversion to CC. Again, other contributing factors for GVHD might have played a significant role. As discussed above, cytokine release may be increased with more intensive regimens such as FB/ATG and FM, and these cytokines are involved in the pathogenesis of GVHD. The impression of this group when comparing FM and Flag/Ida was that relapse rate was higher in patients achieving MC. 5 This could be because MC was tested in unseparated bone marrow cells and therefore could be representing residual leukemia. However, it could be related to a loss of GVL effect. This group has shown that most long-term survivors had GVHD and its occurrence was very important in predicting outcome 5 relating to the known association between GVHD and GVL. 51 Other groups have shown that MC, and especially rising levels of host chimerism, predict impeding relapse, and can revert with DLI. GVHD rates among the mixed chimeras reported in these studies were low. [52] [53] [54] Lion et al 43 have shown that following ablative, mostly T-depleted transplant, MC in the cellular population enriched for leukemic cells by immunophenotype preceded relapse by 3-6 months. Interestingly, in a few patients, relapse was heralded by persistence or recurrence of autologous cells in the T lymphocyte compartment. The setting of impeding graft rejection as detected by T cell MC facilitated subsequent relapse.
However, the requirement for CC to achieve GVT may depend on the type of underlying malignancy. MC has been shown to be associated with increased relapse rate mostly in aggressive malignancies such as AML, and in this setting warrants early intervention. However, in indolent malignancies, such as low-grade lymphoproliferative disorders, disease response may occur gradually, over several months, even in mixed chimeras, and early intervention is not needed unless there is a plateau in the response (I Khouri, personal communication). The Boston group has also shown that CC was not necessary for the occurrence of GVHD. 36 This may have been related to the setting of HLA-mismatched transplants. Interestingly, this group has shown in a murine model, that DLI is more effective in eliminating malignant cells in recipients with MC that in those with CC. 55 This may be explained by persistence of host antigen-presenting cells in the mixed chimera, with better capacity for alloactivation.
Chimerism testing is a critical aspect of patient management after non-myeloablative transplantation and directs clinical interventions. CC is the objective of treatment of patients with aggressive malignant disorders because it may be necessary for the development of anti-tumor responses. It may not be necessary, at least initially, in non-malignant disorders as long as a stable graft can be maintained. 56 It may also not be required in indolent malignancies. The first manipulation attempted trying to convert to CC is discontinuation of immunosuppressive therapy. This is usually begun at 30-60 days post transplant. 9, 11, 30, 34 Those not achieving CC within a few weeks, and not developing GVHD, are eligible for DLI, usually administered at monthly intervals, until CC and/or GVHD occur. GVHD and conversion to CC often occur together because of association between anti-hematopoietic tissue effect and GVHD, but GVHD is not necessary for the conversion. The timing of these manipulations is critical. Early intervention in the setting of decreasing donor chimerism may protect the graft from rejection, however, increases the risk for GVHD. Clinical judgment based on serial chimerism testing is necessary. We recommend weekly assessment of chimerism until conversion to CC and stability are achieved. Less frequent testing at approximately 2-4 weeks are recommended thereafter. Testing of different lineages has important advantages. T cell chimerism predicts allogeneic responses and is not affected by residual myeloid malignancy. Complete myeloid chimerism may lag behind T cell chimerism and depend on anti-hematopoietic tissue effect or elimination of residual leukemia. 9 The kinetics of engraftment following reduced-intensity NST is somewhat similar to that after ablative conditioning. Following these regimens we recommend testing for chimerism monthly during the first 3 months, unless MC is found at engraftment, and every 3 months thereafter. Most patients achieve CC spontaneously with no need for immune-therapeutic manipulations. The prompt achievement of CC allows the early development of anti-tumor effects but also predisposes to GVHD. Immunosuppressive treatment for prevention of GVHD has traditionally been given for 6 months. Some groups reduce this period in patients with high risk for relapse to 3 months to allow early development of GVL effects. However, in low-risk patients and following unrelated donor transplants, most groups complete a 6-month course in patients with CC.
Chimerism testing is also important in the late post-transplant period. As stated above, the balance that was achieved at the time of engraftment may switch towards graft rejection and autologous reconstitution. 5 These changes in the degree of chimerism may be gradual and occult and may not present with a period of pancytopenia, been recognized only by routine chimerism testing. The phenomenon of occult late rejection and autologous reconstitution was first reported in patients with aplastic anemia following the standard non-ablative regimens used in this disease. 57 Occult rejection when the balance in MC switches to autologous reconstitution most often occurs 2-4 months after NST 5, 34 and should be differentiated from recurrent disease, most typical of CML, when autologous leukemic hematopoiesis gradually replaces donor hematopoiesis. Occult late rejection and autologous reconstitution may occur even in those achieving CC. 57 MC, especially when tested on unseparated marrow cells, may represent residual disease, and predispose to relapse. Several groups have shown that sequential monitoring of chimerism after transplant is predictive of relapse of the underlying malignancy. Assessment of MRD using a specific marker when available is recommended in this setting. Chimerism analysis may detect recurrent disease weeks to months before hematological relapse. More frequent testing is needed for diseases with rapid dynamics of recurrence such as AML and CML in blast crisis for early detection. Rising host chimerism may direct earlier immune manipulations such as withdrawal of immunosuppressive therapy and DLI, to prevent relapse. [52] [53] [54] Prophylactic DLI is sometimes scheduled for about 3 months post NST for patients at high risk of relapse. Timing of these manipulations depends on occurrence of GVHD and disease progression.
Chimerism testing is important in predicting the response to DLI. It is now appreciated that low-level donor chimerism may not convert to CC with DLI, and other interventions need to be explored to salvage these grafts. 9, 48 Pancytopenia after DLI is more common in patients with low-level donor chimerism because of elimination of host hematopoiesis that contributed to a larger fraction of hematopoiesis prior to DLI. 58 This is more common in patients with CML. CML cells have exquisite sensitivity to donor immunity and conversion to CC is possible even in patients with minute levels of donor chimerism often with a period of pancytopenia. Assessment of chimerism status is also important when planning a second BMT for treatment of recurrent disease. Persistence of donor cells ensures that tolerance to donor graft is maintained and rejection is unlikely.
Chimerism testing post BMT also helps in the diagnosis of rare disorders such as donor cell malignancies and transfusion-associated GVHD.
Summary and conclusions
NST is becoming a widely accepted treatment modality for a wide range of indications. NST regimens form a continuum of myelosuppressive and immunosuppressive intensity, from non-myeloablative regimens to the more myelosuppressive, reduced-intensity regimens. The non-myeloablative regimens intentionally induce a state of mixed chimerism. These regimens reduce toxicity by the use of less intensive, non-toxic conditioning, and MC describes a state of bilateral tolerance with the potential of limiting the occurrence of GVHD. Reduced-intensity regimens rapidly induce CC and anti-tumor responses, but are more toxic, and associated with higher risk for GVHD. The selection of the appropriate regimen for a patient depends on several factors including age, general medical condition, immune competence of the recipient and genetic disparity between the patient and donor. Perhaps the most important determining factor is the aggressiveness and chemosensitivity of the underlying malignancy. The reduced intensity regimens are a more appropriate approach for aggressive malignancies such as AML, and especially when not in remission. In this setting rapid achievement of CC and transient disease control is needed to induce GVL. However, Leukemia in indolent malignancies GVL may occur slowly, even in mixed chimeras, and toxicity may be reduced further using non-myeloablative regimens. Close monitoring of chimerism by sensitive chimerism testing is critical to guide the timely introduction of immune-therapeutic interventions. Early withdrawal of immunosuppressive therapy followed if necessary by DLI can eliminate residual host hematopoiesis and malignancy, however it also predisposes the NST recipient to GVHD. Early intervention is needed in the face of decreasing donor chimerism after NST in order to prevent rejection, but may be delayed in patients with a high degree of donor chimerism and no residual disease in order to reduce the risks.
Close monitoring of chimerism is less informative following reduced-intensity NST regimens since most recipients promptly achieve complete chimerism with no need for immune-therapeutic interventions.
GVHD continues to be a major obstacle for the success of these regimens. Better understanding of the biology of graft rejection, GVHD and GVL will allow introduction of specific interventions to prevent or induce the desired effects. Much progress has already been achieved. Animal models have been developed such that the prevention of rejection is achieved with regimens with no chemotherapy, such as with costimulation blockade alone. 20 DLI can be made more specific and target-directed by the generation of specific T cell clones against hematopoietic or tumor-specific antigens. 59 Alloreactive T cells with GVHD potential may be eliminated from the stem cell preparation with various techniques. BMT in the twenty-first century will focus on specific targeted immunotherapy rather than on massive toxic doses of chemotherapy and radiation, allowing safer application of curative approach to a wider range of patients and diseases. Sensitive chimerism testing and testing of MRD will be critical in guiding clinical decision-making and immune-therapeutic manipulations.
